Lupus & antiphospholipid syndrome
A BAFF/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study
Authors' conclusion
This real-world study demonstrated that telitacicept is both efficacious and safe and can effectively reduce disease activity and improve serological indices.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) treated with telitacicept at Peking Union Medical College Hospital, May 2021 to October 2025
- Participants
- 110 patients
- Outcome
- SRI-4 response
- Follow-up
- 2, 4, 6, 12, 18, 24 and 36 months
Methodological detailslong-term, single-centre, observational, real-world, Maximum observation point 36 months; patients retrospectively enrolled
- Long-term
- Single-centre
- Observational
- Real-world
- Maximum observation point 36 months; patients retrospectively enrolled
Main finding
As reported in the abstract
- SRI-4 response at 2 months
- 31%
- SRI-4 response at 4 months
- 49%
- SRI-4 response at 6 months
- 55%
- SRI-4 response at 12 months
- 60%
- SRI-4 response at 18 months
- 74%
- SRI-4 response at 24 months
- 61%
- SRI-4 response at 36 months
- 65%
Observational data: associations, not effects.
Further findings
SLEDAI-2K, immunoglobulin, anti-dsDNA, GC dose; complements 3 and 4 · 6, 12, 18, 24 and 36 months
- SLEDAI-2K, immunoglobulin, anti-dsDNA and GC dose all decreased significantly; complements 3 and 4 increased significantly
Renal parameters (renal involvement subgroup)
- 24-hour urine protein, serum creatinine and serum albumin significantly improved
Hematologic parameters (hematologic involvement subgroup)
- Platelet count, hemoglobin and white blood cell count significantly increased
Safety
- Incidence of adverse events
- 34%
- Infection
- 25.5%
- Serious adverse events
- 0
Original publication
A BAFF/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study. Arthritis Res Ther. Published 16 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →